Anthony Cerami
#16,298
Most Influential Person Now
American scientist
Anthony Cerami's AcademicInfluence.com Rankings
Anthony Ceramibiology Degrees
Biology
#937
World Rank
#1633
Historical Rank
#502
USA Rank
Molecular Biology
#95
World Rank
#98
Historical Rank
#59
USA Rank
Biochemistry
#112
World Rank
#145
Historical Rank
#64
USA Rank
Download Badge
Biology
Anthony Cerami's Degrees
- Bachelors Chemistry Fordham University
Why Is Anthony Cerami Influential?
(Suggest an Edit or Addition)According to Wikipedia, Anthony Cerami is an American entrepreneur and medical research scientist. Biography Anthony Cerami received his undergraduate degree from Rutgers University and received a Ph.D. in 1967 from Rockefeller University, New York, completed postdoctoral fellowships at Harvard Medical School and at the Jackson Laboratory and served for 20 years as Professor and Head of the Laboratory of Medical Biochemistry, and Dean of Graduate and Postgraduate Studies at Rockefeller.
Anthony Cerami's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. (1988) (2603)
- Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia (1987) (2498)
- Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. (1985) (2405)
- The biology of cachectin/TNF--a primary mediator of the host response. (1989) (1729)
- Detection of circulating tumor necrosis factor after endotoxin administration. (1988) (1677)
- Cachectin and tumour necrosis factor as two sides of the same biological coin (1986) (1616)
- Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators. (1986) (1501)
- Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1 (1986) (1474)
- Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. (2000) (1421)
- Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. (1986) (1302)
- Circulating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair (1994) (1299)
- Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. (1976) (1294)
- Cachectin: more than a tumor necrosis factor. (1987) (1231)
- Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts (1985) (1227)
- Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. (1991) (1211)
- Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. (1986) (1186)
- MIF as a glucocorticoid-induced modulator of cytokine production (1995) (1137)
- Identity of tumour necrosis factor and the macrophage-secreted factor cachectin (1985) (1126)
- Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. (1994) (1098)
- Nonenzymatic glycosylation and the pathogenesis of diabetic complications. (1984) (1067)
- Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial (2002) (1047)
- Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress (2001) (1035)
- Advanced glycosylation end products in patients with diabetic nephropathy. (1991) (916)
- MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia (1993) (861)
- Tumor necrosis factor, other cytokines and disease. (1993) (826)
- Tumor necrosis, cachexia, shock, and inflammation: a common mediator. (1988) (821)
- Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic (2004) (803)
- Protein glycation, diabetes, and aging. (2001) (797)
- Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells (1985) (791)
- Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. (1985) (777)
- Advanced glycation end products contribute to amyloidosis in Alzheimer disease. (1994) (772)
- Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation (1988) (744)
- Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. (1981) (738)
- Metabolism and functions of trypanothione in the Kinetoplastida. (1992) (715)
- Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. (2004) (675)
- Accelerated age-related browning of human collagen in diabetes mellitus. (1984) (648)
- Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling (2003) (632)
- Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. (1985) (614)
- Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites (1992) (610)
- Lipid advanced glycosylation: pathway for lipid oxidation in vivo. (1993) (579)
- Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties (1988) (568)
- Cytokine appearance in human endotoxemia and primate bacteremia. (1988) (548)
- Erythropoietin Selectively Attenuates Cytokine Production and Inflammation in Cerebral Ischemia by Targeting Neuronal Apoptosis (2003) (526)
- Tobacco smoke is a source of toxic reactive glycation products. (1997) (524)
- Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury (2002) (508)
- Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. (1992) (504)
- Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage (2011) (495)
- A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. (1985) (492)
- Immunochemical detection of advanced glycosylation end products in vivo. (1992) (491)
- The biochemistry of the complications of diabetes mellitus. (1981) (480)
- An iron-carboxylate bond links the heme units of malaria pigment. (1991) (477)
- Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. (1994) (469)
- An agent cleaving glucose-derived protein crosslinks in vitro and in vivo (1996) (455)
- Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo (2003) (448)
- Identification and characterization of macrophage inflammatory protein 2. (1989) (443)
- Breakers of advanced glycation end products restore large artery properties in experimental diabetes. (1998) (441)
- Hemoglobin degradation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle. (1990) (440)
- Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses (1988) (439)
- Peptide Regulatory Factors CACHECTIN/TUMOUR NECROSIS FACTOR (1989) (435)
- Macrophage inflammatory proteins 1 and 2: members of a novel superfamily of cytokines (1989) (426)
- Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury (2002) (425)
- Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). (1994) (421)
- Identification of Galectin-3 As a High-Affinity Binding Protein for Advanced Glycation End Products (AGE): A New Member of the AGE-Receptor Complex (1995) (406)
- Infection and labor. IV. Cachectin-tumor necrosis factor in the amniotic fluid of women with intraamniotic infection and preterm labor. (1989) (405)
- Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma (2002) (399)
- Diabetic cataract formation: potential role of glycosylation of lens crystallins. (1978) (393)
- The role of cytokines in the generation of inflammation and tissue damage in experimental gram-positive meningitis (1990) (390)
- Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure (1994) (373)
- Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. (1992) (373)
- The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. (1990) (361)
- Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. (1984) (358)
- Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. (1988) (358)
- The role of cachectin/TNF in endotoxic shock and cachexia. (1988) (348)
- An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. (2000) (347)
- Macrophage inflammatory protein 1 modulates macrophage function. (1992) (339)
- Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. (1992) (338)
- Glucose and aging. (1987) (327)
- Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis (2002) (327)
- Erythropoietin‐mediated tissue protection: reducing collateral damage from the primary injury response (2008) (325)
- Acetaldehyde adducts with hemoglobin. (1981) (325)
- Tumor necrosis factor: An updated review of its biology (1993) (315)
- High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. (1985) (313)
- Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin (2008) (308)
- Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. (2006) (298)
- Spermine Inhibits Proinflammatory Cytokine Synthesis in Human Mononuclear Cells: A Counterregulatory Mechanism that Restrains the Immune Response (1997) (295)
- Studies of endotoxin-induced decrease in lipoprotein lipase activity (1981) (294)
- Cloning and characterization of cDNAs for murine macrophage inflammatory protein 2 and its human homologues (1990) (294)
- Emerging biological roles for erythropoietin in the nervous system (2005) (291)
- Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: implications for recruitment of leukocytes into brain and lymph nodes. (1996) (291)
- Hemoglobin-AGE: a circulating marker of advanced glycosylation. (1992) (282)
- Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. (1989) (277)
- Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts (1991) (274)
- Hemoglobin AIc as an indicator of the degree of glucose intolerance in diabetes (1976) (274)
- Erythropoietin both protects from and reverses experimental diabetic neuropathy. (2004) (269)
- Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis (1989) (269)
- Genomic cloning and promoter analysis of macrophage inflammatory protein (MIP)-2, MIP-1 alpha, and MIP-1 beta, members of the chemokine superfamily of proinflammatory cytokines. (1993) (267)
- A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. (2001) (264)
- Hypothesis. Glucose as a mediator of aging. (1985) (264)
- Comparative analysis of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells. Interacting effects involving suppression, synergistic suppression, and blocking of suppression. (1993) (261)
- Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease (1991) (260)
- Cachectin (tumor necrosis factor): a macrophage hormone governing cellular metabolism and inflammatory response. (1988) (251)
- Hypertriglyceridemia associated with Trypanosoma brucei brucei infection in rabbits: role of defective triglyceride removal. (1980) (250)
- Enhancing and suppressing effects of recombinant murine macrophage inflammatory proteins on colony formation in vitro by bone marrow myeloid progenitor cells. (1990) (247)
- A glucose-controlled insulin-delivery system: semisynthetic insulin bound to lectin. (1979) (247)
- Emerging biological roles for erythropoietin in the nervous system (2005) (244)
- Cachectin/tumor necrosis factor‐α alters red blood cell kinetics and induces anemia in vivo (1989) (242)
- Resolution of the two components of macrophage inflammatory protein 1, and cloning and characterization of one of those components, macrophage inflammatory protein 1 beta (1988) (239)
- Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. (1990) (238)
- Effect of gamma interferon on cachectin expression by mononuclear phagocytes. Reversal of the lpsd (endotoxin resistance) phenotype (1986) (238)
- A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. (2005) (237)
- Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia. (1990) (234)
- Tumour necrosis factor production in Falciparum malaria and its association with schizont rupture. (1989) (234)
- Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells. (1982) (230)
- Purification and characterization of trypanothione reductase from Crithidia fasciculata, a newly discovered member of the family of disulfide-containing flavoprotein reductases. (1986) (229)
- Anticachectin/tumor necrosis factor‐α antibodies attenuate development of cachexia in tumor models (1989) (220)
- Macrophage inflammatory protein-1: a prostaglandin-independent endogenous pyrogen. (1989) (217)
- Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. (1985) (216)
- Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. (1981) (214)
- Nonenzymatic Glycosylation Products on Collagen Covalently Trap Low-Density Lipoprotein (1985) (213)
- Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. (1992) (212)
- Modification of DNA by reducing sugars: a possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. (1984) (209)
- CACHECTIN: MORE THAN A TUMOR NECROSIS FACTOR (1988) (208)
- Structure of carbohydrate of hemoglobin AIc. (1977) (207)
- Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. (1988) (206)
- Potassium cyanate as an inhibitor of the sickling of erythrocytes in vitro. (1971) (204)
- Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). (1985) (199)
- Collagen Aging In Vitro by Nonenzymatic Glycosylation and Browning (1984) (198)
- Erythropoietin: a candidate compound for neuroprotection in schizophrenia (2004) (198)
- Cachectin (Tumor Necrosis Factor) (1988) (195)
- Differential regulation of transforming growth factor beta and interleukin 2 genes in human T cells: demonstration by usage of novel competitor DNA constructs in the quantitative polymerase chain reaction (1991) (195)
- Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins (1991) (194)
- In vivo effects of difluoromethylornithine on trypanothione and polyamine levels in bloodstream forms of Trypanosoma brucei. (1987) (190)
- Cachectin/tumour necrosis factor. (1989) (189)
- Trypanothione is the primary target for arsenical drugs against African trypanosomes. (1989) (186)
- Cloning and characterization of a cDNA for murine macrophage inflammatory protein (MIP), a novel monokine with inflammatory and chemokinetic properties [published erratum appears in J Exp Med 1989 Dec 1;170(6):2189] (1988) (181)
- Nonenzymatic glycosylation of hemoglobin. (1977) (175)
- Covalent attachment of soluble proteins by nonenzymatically glycosylated collagen. Role in the in situ formation of immune complexes (1983) (171)
- Cachectin: a hormone that triggers acute shock and chronic cachexia. (1988) (171)
- Excessive Nonenzymatic Glycosylation of Peripheral and Central Nervous System Myelin Components in Diabetic Rats (1983) (170)
- The common mediator of shock, cachexia, and tumor necrosis. (1988) (169)
- Nonenzymatic glycosylation, sulfhydryl oxidation, and aggregation of lens proteins in experimental sugar cataracts (1979) (169)
- MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia (1995) (167)
- Malaria-specific metabolite hemozoin mediates the release of several potent endogenous pyrogens (TNF, MIP-1 alpha, and MIP-1 beta) in vitro, and altered thermoregulation in vivo. (1995) (167)
- Cachetin/TNF-α in Septic Shock and Septic Adult Respiratory Distress Syndrome (1988) (164)
- Cachectin/tumor necrosis factor mediates changes of skeletal muscle plasma membrane potential (1986) (164)
- Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors (1986) (160)
- Tumor necrosis factor alpha/cachectin is a growth factor for thymocytes. Synergistic interactions with other cytokines (1988) (158)
- Reduced Functional Deficits, Neuroinflammation, and Secondary Tissue Damage after Treatment of Stroke by Nonerythropoietic Erythropoietin Derivatives (2007) (156)
- "Subversive" substrates for the enzyme trypanothione disulfide reductase: alternative approach to chemotherapy of Chagas disease. (1988) (154)
- Accumulation of diabetic rat peripheral nerve myelin by macrophages increases with the presence of advanced glycosylation endproducts (1984) (147)
- Nonenzymatic glycosylation: role in the pathogenesis of diabetic complications. (1986) (145)
- The history, properties, and biological effects of cachectin. (1988) (144)
- Nonenzymatic Glycosylation Reduces the Susceptibility of Fibrin to Degradation by Plasmin (1983) (144)
- Role of Glycation in Aging (1992) (143)
- A novel addition to the T cell repertory. Cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells (1990) (143)
- Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. (1995) (139)
- Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone (1996) (138)
- Inhibition of glutathione synthesis as a chemotherapeutic strategy for trypanosomiasis (1981) (137)
- Cytokine production in a model of wound healing: the appearance of MIP-1, MIP-2, cachectin/TNF and IL-1. (1990) (136)
- AIDS Dementia Is Associated with Massive, Activated HIV-1 Infection and Concomitant Expression of Several Cytokines (1996) (134)
- Identification of the Major Site of Apolipoprotein B Modification by Advanced Glycosylation End Products Blocking Uptake by the Low Density Lipoprotein Receptor (*) (1995) (133)
- Selective inhibition of synthesis of enzymes for de novo fatty acid biosynthesis by an endotoxin-induced mediator from exudate cells. (1983) (132)
- Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. (2006) (129)
- Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury. (2005) (128)
- Identification of a novel, thiol-containing co-factor essential for glutathione reductase enzyme activity in trypanosomatids. (1985) (126)
- Effect of endotoxin-induced monokines on glucose metabolism in the muscle cell line L6. (1987) (125)
- Synthesis of hemoglobin AIc in normal and diabetic mice: potential model of basement membrane thickening. (1975) (122)
- An Inhibitor of Macrophage Arginine Transport and Nitric Oxide Production (CNI-1493) Prevents Acute Inflammation and Endotoxin Lethality (1995) (121)
- The Receptor That Tames the Innate Immune Response (2012) (120)
- Role of advanced glycosylation products in complications of diabetes. (1988) (119)
- ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes (2015) (113)
- Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis (2006) (113)
- Role of nonenzymatic glycosylation in the development of the sequelae of diabetes mellitus. (1979) (113)
- Haem polymerization in malaria (1995) (112)
- Metabolic Responses to Cachectin/TNF (1990) (112)
- Myelopoietic enhancing effects of murine macrophage inflammatory proteins 1 and 2 on colony formation in vitro by murine and human bone marrow granulocyte/macrophage progenitor cells (1989) (111)
- Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. (1995) (110)
- COMPARATIVE ANALYSIS OF THE HUMAN MACROPHAGE INFLAMMATORY PROTEIN FAMILY OF CYTOKINES (CHEMOKINES) ON PROLIFERATION OF HUMAN MYELOID PROGENITOR CELLS (1993) (109)
- Intervention With an Erythropoietin-Derived Peptide Protects Against Neuroglial and Vascular Degeneration During Diabetic Retinopathy (2011) (107)
- TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury (2008) (107)
- Erythropoietin as a Tissue-Protective Cytokine in Brain Injury: What Do We Know and Where Do We Go? (2004) (107)
- Recombinant human cachectin/tumor necrosis factor but not interleukin-1 alpha downregulates lipoprotein lipase gene expression at the transcriptional level in mouse 3T3-L1 adipocytes (1988) (106)
- Positive and negative regulation of APP amyloidogenesis by sumoylation (2003) (106)
- Cachectin/tumor necrosis factor: An endogenous mediator of shock and inflammation (1986) (104)
- Isolation and characterization of a proteolytic enzyme from the adult hookworm Ancylostoma caninum. (1985) (103)
- Role of cyclophilin A in the uptake of HIV-1 by macrophages and T lymphocytes. (1998) (103)
- Verapamil Reversal of Chloroquine Resistance in the Malaria Parasite Plasmodium falciparum Is Specific for Resistant Parasites and Independent of the Weak Base Effect (*) (1995) (102)
- Protective Effect of Erythropoietin and Its Carbamylated Derivative in Experimental Cisplatin Peripheral Neurotoxicity (2006) (102)
- CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. (1996) (99)
- Interleukin 1 beta is expressed predominantly by enterocytes in experimental colitis. (1991) (98)
- Trypanothione dependent peroxide metabolism in Crithidia fasciculata and Trypanosoma brucei. (1987) (98)
- Detection of an advanced glycosylation product bound to protein in situ. (1985) (96)
- Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection (2009) (95)
- Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study (2012) (95)
- Iron-containing superoxide dismutase from Crithidia fasciculata. Purification, characterization, and similarity to Leishmanial and trypanosomal enzymes. (1983) (94)
- Formation of covalent adducts between cortisol and 16 alpha-hydroxyestrone and protein: possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus. (1982) (93)
- Neuroprotective properties of epoetin alfa. (2002) (93)
- Tumor necrosis factor (1993) (92)
- Secretion of a proteolytic anticoagulant by Ancylostoma hookworms (1983) (91)
- Non-enzymatic glycosylation and browning of proteins in diabetes. (1982) (91)
- The identification of 2, 3-dihydroxybenzoic acid as a potentially useful iron-chelating drug. (1974) (91)
- Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts. (1984) (90)
- Elevated glucose 6-phosphate levels are associated with plasmid mutations in vivo. (1987) (89)
- Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the ‘AMC-Senshu’ method (2012) (88)
- Processing of newly synthesized cachectin/tumor necrosis factor in endotoxin-stimulated macrophages. (1990) (88)
- Tumor Necrosis Factor and Regulation of Metabolism in Infection: Role of Systemic versus Tissue Levels (1992) (88)
- ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density (2013) (87)
- Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative. (2006) (87)
- Inhibition of Heparin-Catalyzed Human Antithrombin III Activity by Nonenzymatic Glycosylation: Possible Role in Fibrin Deposition in Diabetes (1984) (85)
- Cerebroprotective effects of aminoguanidine in a rodent model of stroke. (1996) (85)
- Cytotoxicity of a perfluorocarbon blood substitute to macrophages in vitro. (1983) (85)
- Human decidua: a source of cachectin-tumor necrosis factor. (1991) (85)
- The acetylation of hemoglobin by aspirin. In vitro and in vivo. (1975) (83)
- Substrate specificity of the flavoprotein trypanothione disulfide reductase from Crithidia fasciculata. (1987) (82)
- Recognition and Uptake of Human Diabetic Peripheral Nerve Myelin by Macrophages (1985) (82)
- Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. (2017) (81)
- Advanced glycosylation endproducts on erythrocyte cell surface induce receptor-mediated phagocytosis by macrophages. A model for turnover of aging cells (1987) (81)
- The effects of cyanate in vitro on red blood cell metabolism and function in sickle cell anemia. (1972) (81)
- Myelosuppressive effects in vivo of purified recombinant murine macrophage inflammatory protein-1 alpha. (1992) (79)
- Effects of iron chelators and iron overload on Salmonella infection (1977) (79)
- Specific Macrophage Receptor Activity for Advanced Glycosylation End Products Inversely Correlates With Insulin Levels In Vivo (1988) (78)
- Measurement of Glycosylated Amino Acids and Peptides from Urine of Diabetic Patients Using Affinity Chromatography (1980) (77)
- AND DIABETES MELLITUS (1980) (77)
- X-ray structure of trypanothione reductase from Crithidia fasciculata at 2.4-A resolution. (1991) (77)
- Leishmania promastigotes are recognized by the macrophage receptor for advanced glycosylation endproducts (1987) (76)
- The involvement of TNF, IL-1 and IL-6 in the immune response to protozoan parasites. (1991) (76)
- Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptor. (2013) (75)
- Interferon-gamma overcomes glucocorticoid suppression of cachectin/tumor necrosis factor biosynthesis by murine macrophages. (1990) (75)
- DNA amplification in experimental pneumocystosis: characterization of serum Pneumocystis carinii DNA and potential P. carinii carrier states. (1993) (75)
- Infection and labor. IV. Cachectin‐tumor necrosis factor in the amniotic fluid of women with intraamniotic infection and preterm labor (1990) (74)
- Cachectin/TNF production in experimental burns and Pseudomonas infection. (1988) (73)
- Increased survival of sickle-cell erythrocytes after treatment in vitro with sodium cyanate. (1971) (73)
- Modification of DNA by glucose 6-phosphate induces DNA rearrangements in an Escherichia coli plasmid. (1985) (73)
- Novel pyrroles from sulfite-inhibited Maillard reactions: insight into the mechanism of inhibition (1988) (72)
- Inhibition of advanced glycation endproduct formation by acetaldehyde: role in the cardioprotective effect of ethanol. (1999) (72)
- Comparative analysis of DNA mutations in lacI transgenic mice with age (1994) (72)
- Biochemical studies of the nucleoside analogue, formycin. (1969) (72)
- The interaction of actinomycin with DNA: requirement for the 2-amino group of purines. (1967) (70)
- Macrophage inflammatory protein-1: Unique action on the hypothalamus to evoke fever (1990) (70)
- Studies of insulin resistance in adipocytes induced by macrophage mediator (1983) (70)
- Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. (2015) (70)
- Prevention and treatment of experimental autoimmune encephalomyelitis by CNI-1493, a macrophage-deactivating agent. (1998) (70)
- An approach to the development of new drugs for African trypanosomiasis (1978) (69)
- Nonenzymatic Glycosylation and Browning in Diabetes and Aging: Studies on Lens Proteins (1982) (69)
- Effects of epoetin alfa on the central nervous system. (2001) (69)
- Reduced plasma lipoprotein lipase activity in patients with malignancy-associated weight loss. (1986) (69)
- Immunologic Characterization and Quantification of Haemoglobin A1c (1978) (69)
- Interleukin‐2 Initiates Metabolic Responses Associated with Critical Illness in Humans (1988) (68)
- Characterization of a solubilized cell surface binding protein on macrophages specific for proteins modified nonenzymatically by advanced glycosylated end products. (1988) (68)
- Aging of proteins and nucleic acids: what is the role of glucose? (1986) (67)
- Pharmacology of cyanate. I. General effects on experimental animals. (1973) (67)
- Correlation of Serum Triglyceride Levels and Hemoglobin AIc Concentrations in Diabetes Mellitus (1977) (67)
- The endogenous mediator of endotoxic shock. (1987) (66)
- Beyond erythropoiesis: novel applications for recombinant human erythropoietin. (2001) (66)
- Protein glycosylation and the pathogenesis of atherosclerosis. (1985) (65)
- Macrophage inflammatory protein (MIP)-1 beta abrogates the capacity of MIP-1 alpha to suppress myeloid progenitor cell growth. (1991) (65)
- Application of DNA amplification to pneumocystosis: presence of serum Pneumocystis carinii DNA during human and experimentally induced Pneumocystis carinii pneumonia (1992) (64)
- Heme lysis of the bloodstream forms of Trypanosoma brucei. (1977) (64)
- Sodium cyanate as a potential treatment for sickle-cell disease. (1974) (64)
- Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin (2010) (63)
- Corneal confocal microscopy: ready for prime time (2020) (63)
- Isolation of Surface Binding Protein Specific for Advanced Glycosylation End Products From Mouse Macrophage-Derived Cell Line RAW 264.7 (1990) (63)
- Cachectin: its impact on metabolism and nutritional status. (1988) (63)
- A Small Nonerythropoietic Helix B Surface Peptide Based upon Erythropoietin Structure Is Cardioprotective against Ischemic Myocardial Damage (2011) (62)
- Lipopolysaccharide-treated RAW 264.7 cells produce a mediator that inhibits lipoprotein lipase in 3T3-L1 cells. (1985) (62)
- Glycosylated Insulin Complexed to Concanavalin A: Biochemical Basis for a Closed-Loop Insulin Delivery System (1983) (62)
- A Role for DNA Mutations in Diabetes-Associated Teratogenesis in Transgenic Embryos (1995) (62)
- Cachectin/tumor necrosis factor and other cytokines in infectious disease. (1989) (61)
- Glucocorticoid-lens protein adducts in experimentally induced steroid cataracts. (1985) (60)
- Cachectin/TNF-mediated lactate production in cultured myocytes is linked to activation of a futile substrate cycle. (1993) (60)
- Increased Expression of Erythropoietin Receptor on Blood Vessels in the Human Epileptogenic Hippocampus with Sclerosis (2004) (59)
- Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia (2006) (59)
- Detection of nonenzymatic browning products in the human lens. (1983) (59)
- Exonuclease VI, a new nuclease activity associated with E. coli DNA polymerase. (1968) (57)
- The biosynthesis of trypanothione and N1-glutathionylspermidine in Crithidia fasciculata. (1986) (57)
- Hemoglobin A Ic and diabetes mellitus. (1980) (56)
- The development of new iron-chelating drugs. (1976) (56)
- Carbamylated Erythropoietin Reduces Radiosurgically-Induced Brain Injury (2006) (54)
- Mechanism of Inhibition of Advanced Glycosylation by Aminoguanidine in Vitro (1993) (53)
- Effect of various iron chelating agents on DNA synthesis in human cells. (1980) (52)
- Nonerythropoietic Tissue Protective Compounds Are Highly Effective Facilitators of Wound Healing (2009) (52)
- Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns (2013) (51)
- Role of nonenzymatic glycosylation in atherogenesis (1986) (50)
- Macrophage migration inhibitory factor is a neuroendocrine mediator of endotoxaemia. (1994) (50)
- ARA290, a Peptide Derived from the Tertiary Structure of Erythropoietin, Produces Long-term Relief of Neuropathic Pain: An Experimental Study in Rats and &bgr;-Common Receptor Knockout Mice (2011) (49)
- Tumor necrosis factor as a pharmacological target. (2005) (49)
- Small cytokine superfamily. (1991) (49)
- Pyrimidine biosynthesis in parasitic protozoa: purification of a monofunctional dihydroorotase from Plasmodium berghei and Crithidia fasciculata. (1990) (48)
- Iron metabolism, sickle cell disease, and response to cyanate. (1975) (48)
- Lipoprotein lipase suppression in 3T3‐L1 cells by a haematoprotozoan‐induced mediator from peritoneal exudate cells (1984) (47)
- Inhibition of Hemozoin Formation in Plasmodium falciparum Trophozoite Extracts by Heme Analogs: Possible Implication in the Resistance to Malaria Conferred by the β-Thalassemia Trait (1996) (47)
- Increased Hemoglobin AIc in Diabetic Mice (1976) (47)
- Genomic structure of murine macrophage inflammatory protein-1 alpha and conservation of potential regulatory sequences with a human homolog, LD78. (1991) (46)
- Chelation Studies with 2,3‐Dihydroxybenzoic Acid in Patients with β‐Thalassaemia Major (1976) (45)
- Mechanism of iron chelation in the hypertransfused rat: definition of two alternative pathways of iron mobilization. (1978) (45)
- Engineering the substrate specificity of glutathione reductase toward that of trypanothione reduction. (1991) (44)
- Maillard reactions involving proteins and carbohydrates in vivo: relevance to diabetes mellitus and aging. (1981) (44)
- The formation of reactive intermediate(s) of glucose 6-phosphate and lysine capable of rapidly reacting with DNA. (1987) (44)
- Nonenzymatic Glycosylation and Browning of Proteins In Vivo (1983) (44)
- Purification and characterization of dihydroorotate dehydrogenase from the rodent malaria parasite Plasmodium berghei. (1991) (44)
- Differential expression of the small inducible cytokines GRO α and GROβ by synovial fibroblasts in chronic arthritis: Possible role in growth regulation (1994) (43)
- Aromatic amino acid transamination and methionine recycling in trypanosomatids. (1996) (43)
- Trapped Immunoglobulins on Peripheral Nerve Myelin From Patients With Diabetes Mellitus (1986) (43)
- Nonenzymatic modification of lens crystallins by prednisolone induces sulfhydryl oxidation and aggregate formation: in vitro and in vivo studies. (1985) (43)
- Induction of the Chemokine β Peptides, MIP-1α and MIP-1β, by Lipopolysaccharide Is Differentially Regulated by Immunomodulatory Cytokines γ-IFN, IL-10, IL-4, and TGF-β (1998) (42)
- Nuclear Localization Signal of HIV-1 as a Novel Target for Therapeutic Intervention (1995) (42)
- Purification and properties of dihydroorotate oxidase from Crithidia fasciculata and Trypanosoma brucei. (1983) (42)
- Trypanocidal 1,3-arylene diketone bis(guanylhydrazone)s. Structure-activity relationships among substituted and heterocyclic analogues. (1984) (41)
- Tumor necrosis factor in the malnutrition (cachexia) of infection and cancer. (1992) (41)
- Purification of glutathione reductase from gerbil liver in two steps. (1983) (40)
- ARA 290 for treatment of small fiber neuropathy in sarcoidosis (2014) (39)
- Transposition of an Alu-containing element induced by DNA-advanced glycosylation endproducts. (1993) (38)
- Delayed Administration of Pyroglutamate Helix B Surface Peptide (pHBSP), a Novel Nonerythropoietic Analog of Erythropoietin, Attenuates Acute Kidney Injury (2012) (38)
- Macrophage inflammatory proteins 1 and 2: an overview. (1992) (38)
- Low molecular weight iron-binding factor from mammalian tissue that potentiates bacterial growth (1980) (37)
- Cachectin/TNF mediates the pathophysiological effects of bacterial endotoxin/lipopolysaccharide (LPS). (1988) (37)
- The involvement of TNF, IL-1 and IL-6 in the immune response to protozoan parasites (1991) (37)
- Pleiotropic effects of TNF in infection and neoplasia: beneficial, inflammatory, catabolic, or injurious. (1992) (36)
- Cachectin, cachexia, and shock. (1988) (36)
- A Nonerythropoietic Peptide that Mimics the 3D Structure of Erythropoietin Reduces Organ Injury/Dysfunction and Inflammation in Experimental Hemorrhagic Shock (2011) (36)
- Cachetin/TNF-alpha in septic shock and septic adult respiratory distress syndrome. (1988) (36)
- Cyanate as an inhibitor of red-cell sickling. (1972) (36)
- The reaction of 16α‐hydroxyestrone with erythrocytes in vitro and in vivo (1984) (35)
- Inflammatory cytokines. (1992) (34)
- Biosynthesis of the trypanosomatid metabolite trypanothione: purification and characterization of trypanothione synthetase from Crithidia fasciculata. (1990) (34)
- Characterization of high molecular weight glycosylated forms of murine tumor necrosis factor. (1990) (33)
- Inhibition of Membrane Peroxidation in Thalassaemic Erythrocytes by 2,3‐Dihydroxybenzoic Acid (1976) (33)
- Gas chromatographic determination of the carbamylation of hemoglobin S by cyanate. (1973) (32)
- ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response (2014) (32)
- Advanced glycosylation endproducts: Role in diabetic and non‐diabetic vascular disease (1994) (32)
- The development of new iron-chelating drugs. II. (1978) (32)
- Anti-oestrogen antibodies in users of oral contraceptives and in patients with systemic lupus erythematosus. (1987) (32)
- Physiological responses to cachectin. (1987) (31)
- Biochemical and rheological characterization of sputum mucins from a patient with cystic fibrosis. (1981) (30)
- Critical role of reverse transcriptase in the inhibitory mechanism of CNI-H0294 on HIV-1 nuclear translocation. (1996) (29)
- Inhibition of the growth and differentiation of erythroid precursor cells by an endotoxin-induced mediator from peritoneal macrophages. (1983) (29)
- An ultrastructural study of chronic sodium cyanate-indiuced neuropathy. (1977) (29)
- ASSOCIATION OF INSULIN PUMP THERAPY WITH RAISED SERUM AMYLOID A IN TYPE I DIABETES MELLITUS (1984) (29)
- Lipoprotein Lipase Suppression in 3T3-L1 Cells by an Endotoxin-induced Mediator from Exudate Cells (1984) (28)
- Suppression of Coronary Atherosclerosis by Helix B Surface Peptide, a Nonerythropoietic, Tissue-Protective Compound Derived from Erythropoietin (2013) (27)
- Interleukin-1α expression is inducible by cholinergic stimulation in the rat adrenal gland (1992) (27)
- Cachectin--Tumour necrosis factor: a cytokine that mediates injury initiated by invasive parasites. (1987) (27)
- The Use of Chang Cells Cultured in Vitro to Evaluate Potential Iron Chelating Drugs (1976) (27)
- Modulation of cellular stress response via the erythropoietin/CD131 heteroreceptor complex in mouse mesenchymal-derived cells (2015) (26)
- Detection of Pneumocystis carinii in serum of AIDS patients with Pneumocystis pneumonia by the polymerase chain reaction. (1991) (26)
- Chelation therapy in beta-thalassemia major: a one-year double blind study of 2,3-dihydroxybenzoic acid. (1979) (26)
- Rhodotorulic acid--investigation of its potential as an iron-chelating drug. (1979) (26)
- The role of cachectin/TNF and other cytokines in sepsis. (1991) (25)
- Chronic Administration of Small Nonerythropoietic Peptide Sequence of Erythropoietin Effectively Ameliorates the Progression of Postmyocardial Infarction–Dilated Cardiomyopathy (2013) (25)
- CNI-H0294, a Nuclear Importation Inhibitor of the Human Immunodeficiency Virus Type 1 Genome, Abrogates Virus Replication in Infected Activated Peripheral Blood Mononuclear Cells (1998) (24)
- In vitro and in vivo reactions of nucleic acids with reducing sugars. (1990) (24)
- Protein binding of N-2-mercaptoethyl-1,3-diaminopropane via mixed disulfide formation after oral administration of WR 2721. (1982) (23)
- The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain (2013) (23)
- Hookworm antigens: the potential for vaccination. (1987) (23)
- Ketamine Does Not Produce Relief of Neuropathic Pain in Mice Lacking the β-Common Receptor (CD131) (2013) (23)
- ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitors’ Angiogenic Potential and Homing Ability (2016) (23)
- THE STATUS OF NEW IRON CHELATORS* (1980) (23)
- Studies of conditions and agents that stimulate and inhibit the production of cachectin by macrophages (1984) (23)
- DNA polymerases in parasitic protozoans differ from host enzymes. (1980) (23)
- Studies on the reduction of sputum viscosity in cystic fibrosis using an orally absorbed protected thiol. (1980) (23)
- Effects of trypanothione on the biological activity of irradiated transforming DNA. (1992) (23)
- Correlation between tumor necrosis factor-α (TNF-α)-induced cytoskeletal changes and human collagenase gene induction (1992) (22)
- Increased levels of 16 alpha-hydroxyestrone-modified proteins in pregnancy and in systemic lupus erythematosus. (1985) (22)
- Cachectin: a pluripotent hormone released during the host response to invasion. (1987) (22)
- The in vitro trypanocidal activity of N‐substituted p‐benzoquinone imines: Assessment of biochemical structure‐activity relationships using the Hansch approach (1984) (22)
- Synthesis of the trypanosomatid metabolites trypanothione, and N1-mono- and N8-mono-glutathionylspermidine (1986) (22)
- Other approaches (1995) (21)
- Tumor necrosis factor as a mediator of shock, cachexia and inflammation. (1993) (21)
- Corneal nerve quantification predicts the severity of symptoms in sarcoidosis patients with painful neuropathy (2013) (21)
- The effect of aspirin on sickling and oxygen affinity of erythrocytes. (1973) (21)
- The value of failure: the discovery of TNF and its natural inhibitor erythropoietin (2011) (20)
- Effect of arsenical drugs on glutathione metabolism of Litomosoides carinii. (1983) (20)
- Cloning, sequencing, and demonstration of polymorphism in trypanothione reductase from Crithidia fasciculata. (1992) (20)
- Recent advances in ocular cataract research (1986) (20)
- Pharmaceutical intervention of advanced glycation endproducts. (2008) (20)
- TNF and EPO: major players in the innate immune response: their discovery (2012) (20)
- The effect of chelating agents on iron mobilization in Chang cell cultures (1976) (20)
- HAEMOGLOBIN AIc AND DIABETES MELLITUS (1978) (19)
- Chelation therapy for the treatment of thalassemia. (1977) (19)
- Macrophage receptor-mediated processing and regulation of advanced glycosylation endproduct (AGE)-modified proteins: role in diabetes and aging. (1989) (19)
- The pathophysiologic role of cachectin/TNF in septic shock and cachexia. (1988) (19)
- Tumor necrosis factor as a pharmacological target (2005) (18)
- Preparation of High-Potency, Non-aggregating Insulins Using a Novel Sulfation Procedure (1983) (17)
- The unexpected pathway to the creation of the HbA1c test and the discovery of AGE’s (2012) (17)
- Closing the Loop: Practical and Theoretical (1980) (17)
- Differential expression of the small inducible cytokines GRO alpha and GRO beta by synovial fibroblasts in chronic arthritis: possible role in growth regulation. (1994) (17)
- Porphyrin-induced lysis of Trypanosoma brucei: a role for zinc. (1978) (17)
- A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets (2016) (17)
- Cachetin/TNF: a macrophage protein that induces cachexia and shock. (1988) (17)
- Hemoglobin AIc as a model for the development of the sequelae of diabetes mellitus (1978) (16)
- Erythropoietin Derivate Improves Left Ventricular Systolic Performance and Attenuates Left Ventricular Remodeling in Rats With Myocardial Infarct-Induced Heart Failure (2010) (16)
- Hydroxamic acid oxidation--pharmacological considerations. (1978) (16)
- Seven – Modifications of Proteins and Nucleic Acids by Reducing Sugars: Possible Role in Aging (1990) (16)
- Trypanothione Reductase (1989) (15)
- Industion of γδ transposition in response to elevated glucose-6-phosphate levels (1991) (15)
- Preliminary clinical trials with cyanate. (1972) (15)
- Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science, 1985, 229(4716):869-871. Classical article. (2008) (15)
- Synthesis of a cyclic analog of oxidized glutathione by an intersite reaction in a swollen polymer network (1983) (14)
- Cachectin/tumor necrosis factor production by fetal and newborn rat hepatic macrophages. (1989) (14)
- High-performance liquid chromatographic analysis of biological and chemical heme polymerization. (1995) (14)
- Inhibition of erythroid differentiation of mouse erythroleukemia cells by a macrophage product(s). (1987) (14)
- Nonenzymatic glycosylation of DNA by reducing sugars. (1989) (14)
- The vasoreparative potential of endothelial colony‐forming cells in the ischemic retina is enhanced by cibinetide, a non‐hematopoietic erythropoietin mimetic (2019) (14)
- An experimental model for internal denaturation of linear DNA molecules. (1967) (14)
- Studies of Cachexia in Parasitic Infection (1989) (14)
- Advanced non-enzymatic tissue glycosylation: significance in late diabetic complications. (1989) (14)
- Neurotoxicity of sodium cyanate (1979) (13)
- Structure of lysine adducts with 16α-hydroxyestrone and cortisol (1986) (13)
- Chloroquine uptake, altered partitioning and the basis of drug resistance: evidence for chloride-dependent ionic regulation. (1999) (13)
- The trypanocidal activity of various aromatic bisguanylhydrazones in vivo (1982) (13)
- Erratum: Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo (Proceedings of the National Academy of Sciences of the United States of America (May 27, 2003) 100:11 (6741-6746)) (2003) (13)
- ARA 290 , a Peptide Derived from the Tertiary Structure of Erythropoietin , Produces Long-term Relief of Neuropathic Pain An Experimental Study in Rats and-Common Receptor Knockout Mice (2011) (13)
- Pharmacology of cyanate. II. Effects on the endocrine system. (1973) (13)
- Biomedical science and the Third World: under the volcano. (1989) (13)
- Synthesis and NMR characterization of the trypanosomatid metabolite, N1,N8-bis(glutathionyl)spermidine disulphide (trypanothione disulphide) (1990) (12)
- The erythropoietin analogue ARA290 modulates the innate immune response and reduces Escherichia coli invasion into urothelial cells. (2011) (12)
- The role of cachectin/tumor necrosis factor in AIDS. (1989) (12)
- Effect of cyanate on red blood cell sickling. (1973) (12)
- The effect of chelating agents on iron mobilization in Chang cell cultures. (1976) (11)
- Erythropoietin and engineered innate repair activators. (2013) (11)
- The Use of 14C-Cyanate as a Method for Determining Erythrocyte Survival 1 (1973) (10)
- Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis (2017) (10)
- Rapid Publications Nonenzymatic Glycosylation Products on Collagen Covalently Trap Low-Density Lipoprotein (1985) (10)
- ARA290 Improves Insulin Release and Glucose Tolerance in Type 2 Diabetic Goto-Kakizaki Rats (2015) (10)
- The Biology of Cachectin/Tumor Necrosis Factor (1990) (10)
- Chloroquine resistance is not associated with drug metabolism in Plasmodium falciparum. (1995) (10)
- New compounds: N1,N8-bis(2,3-dihydroxybenzoyl)spermidine and analogs as potential iron-chelating drugs. (1980) (10)
- Fever and feeding: Differential actions of macrophage inflammatory protein-1 (MIP-1), MIP-1α and MIP-1β on rat hypothalamus (1993) (9)
- Potential antitrypanosomal agents. 1,N2-Disubstituted 2-amino-5-hydroxy-4-methylnaphtho[1,2-d]thiazolium salts and related compounds. (1982) (9)
- Characterization of antisera to the addition product formed by the nonenzymatic reaction of 16 alpha-hydroxyestrone with albumin. (1983) (9)
- Preliminary crystallographic analysis of trypanothione reductase from Crithidia fasciculata. (1990) (9)
- Targeting the innate repair receptor to treat neuropathy (2016) (9)
- Accumulation of advanced glycosylation endproducts on proteins and nucleic acids: role in ageing. (1985) (9)
- Chemical and biological aspects of the inhibition of red blood cell sickling by cyanate. (1972) (8)
- Cyanate and sickle-cell disease. (1975) (8)
- Studies with intravenous sodium cyanate in patients with sickle cell anemia. (1974) (8)
- Endogenous cachectin/tumour necrosis factor-alpha production contributes to experimental cancer-associated cachexia. (1989) (8)
- Correlation between tumor necrosis factor-alpha (TNF-alpha)-induced cytoskeletal changes and human collagenase gene induction. (1992) (8)
- Cachectin: the dark side of tumor necrosis factor. (1986) (8)
- The influence of genetic background on the susceptibility of mice to diabetes induced by alloxan and on recovery from alloxan diabetes (1979) (7)
- Molecular Medicine: The Future of Biomedical Science and Clinical Practice (1994) (7)
- Hypothesis (1985) (7)
- Macrophage inflammatory protein-1 (1993) (7)
- Hemoglobin glycosylation as a model for modification of other proteins. (1980) (7)
- Parasites: Molecular biology, drug and vaccine design (1990) (6)
- Interleukin-1 alpha expression is inducible by cholinergic stimulation in the rat adrenal gland. (1992) (6)
- 2,3-DHB ineffective in treatment of iron overload. (1977) (6)
- Fever and feeding: differential actions of macrophage inflammatory protein-1 (MIP-1), MIP-1 alpha and MIP-1 beta on rat hypothalamus. (1993) (6)
- Tumor necrosis factor in metabolism of disease: hormonal actions versus local tissue effects. (1992) (6)
- A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema (2020) (6)
- Erythropoietin in Spinal Cord Injury (2006) (6)
- Host-associated iron transfer factor in normal humans and patients with transfusion siderosis. (1986) (6)
- Induction of gamma delta transposition in response to elevated glucose-6-phosphate levels. (1991) (6)
- REVIEW OF THE DEVELOPMENT OF CYANATE AS A DRUG IN THE TREATMENT OF SICKLE CELL ANEMIA * (1974) (6)
- Cachectin/tumor necrosis factor participates in reduction of skeletal muscle membrane potential: Evidence for bioactivity in plasma during critical illness (1986) (5)
- Therapy of sickle cell disease: an approach with sodium cyanate. (1974) (5)
- Synergism of cimetidine with anti-malarial agents. (1997) (5)
- Letter: "Orphan-drug" development - whose responsibility? (1975) (5)
- Biochemical and physiological properties of carbamylated hemoglobin S. (1974) (5)
- Pillars Article: Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin. Science, 1985, 229(4716):869–871. (2008) (4)
- HIV results in the frame. Other approaches. (1995) (4)
- Antimalarial activity of novel arylene bis(methylketone) compounds. (1996) (4)
- Pharmacological characterization of fever evoked by intrahypothalamic macrophage inflammatory protein-1 (1990) (4)
- Glycohemoglobins in the adult erythrocyte. (1979) (4)
- Chapter 23. The Current Status of Iron Chelation Therapy (1978) (4)
- PHARMACOLOGY OF CYANATE. III. EFFECTS ON THE CENTRAL NERVOUS SYSTEM (1974) (4)
- Modification of hemoglobin by ninhydrin. (1980) (4)
- The Role of the Maillard Reaction In Vivo (2005) (4)
- TRYPANOCIDAL 1,3-ARYLENE DIKETONE BIS(GUANYLHYDRAZONES). STRUCTURE-ACTIVITY RELATIONSHIPS AMONG SUBSTITUTED AND HETEROCYCLIC ANALOGS (1984) (4)
- Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand (2020) (4)
- Preliminary crystallographic analysis of murine macrophage inflammatory protein 2. (1992) (3)
- The formation of hb aic as a biochemical model for the sequelae of diabetes. (1978) (3)
- Cachectin: A Macrophage Protein that Induces a Catabolic State in Infected Animals (1987) (3)
- Novel Pyrroles from Sulfite-Inhibited Maillard Reactions: Insight into the Mechanism of Inhibition. (1988) (3)
- Chemotherapy of trypanosomiasis: the use of guanylhydrazone compounds in the treatment of experimental murine trypanosomiasis. (1987) (3)
- Glycosylation of hemoglobin in the diabetic mouse. Abstr. (1975) (3)
- STUDIES O F I NSULIN R ESISTANCE I N A DIPOCYTES INDUCED BY MACROPHAGE M EDIATOR (1983) (3)
- Isolation of a macrophage receptor for proteins modified by advanced glycosylation end products (1987) (3)
- Non‐enzymatic modification of proteins by steroids: Pathological implications for autoimmunity and glucocorticoid toxicity (1985) (3)
- An Engineered Innate Repair Receptor Agonist, ARA 290, Protects Rat Islets from Cytokine-induced Apoptosis (2016) (3)
- The reaction of 16 alpha-hydroxyestrone with erythrocytes in vitro and in vivo. (1984) (3)
- Carbodiimide-mediated O-sulfation of hydroxy-amino acids and peptides: a reaction suitable for radiolabeling. (1985) (3)
- Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation (2021) (3)
- Micronutrients and immune functions . Cytokines and metabolism (1990) (2)
- Studies on the pharmacological properties of novel arylene bis(methylketone) compounds using solid-phase extraction and high-performance liquid chromatography. (1997) (2)
- Glutathione Reductase in Trypanosomatids (1983) (2)
- SAT0116 Safety and Efficacy of Ara290, a Non-Hematopoietic Erythropoietin Derived Peptide, in a 4 Weeks Phase II Open Label Trial in Patients with Active Rheumatoid Arthritis. (2013) (2)
- Tissue-Protective Cytokines (2013) (2)
- Tumor Necrosis Factor (Cachectin) in Septic/ Endotoxic Shock (2019) (2)
- Hemoglobin adducts with acetaldehyde (1980) (2)
- Infected burn injury alters hepatic monokine and albumin mRNA contents (1988) (2)
- Actions of endotoxin, interleukin-I and tumor-necrosis-factor on arachidonic-acid metabolism in human amnion cells (1987) (2)
- The Biochemical Basis of Cachexia of Infection (1990) (2)
- Nonenzymatic Reaction of Reducing Sugars with DNA (1990) (2)
- Cachectin/Tumor Necrosis Factor-secreting Tumor in Skeletal Muscle Induces Chronic Cachexia, While Implantation in Brain Induces Predominately Acute Anorexia (2)
- Chapter 25 Non-enzymatic Glycosylation (1979) (2)
- Drug development for "orphan" diseases. (1978) (2)
- DEVELOPMENT OF A SELECTIVE INHIBITOR OF CYTOKINE‐INDUCIBLE L‐ARGININE TRANSPORT (CNI‐1493) THAT BLOCKS MACROPHAGE PRODUCTION OF NO AND TNF&agr;, AND PROTECTS AGAINST LPS LETHALITY.: 31 (1995) (2)
- Biomedical science and the third world. Under the volcano. Trypanothione reductase. (1989) (2)
- TUMOR NECROSIS FACTOR, OTHER CYTOKINES AND (1993) (1)
- Glucose-mediated DNA Damage and Mutations: In Vitro and In Vivo (2005) (1)
- The erythropoietin‐derived peptide ARA 284 reduces tissue wasting and improves survival in a rat model of cancer cachexia (2022) (1)
- Epoetin alfa has potential efficacy in central nervous system disorders (2004) (1)
- Hemoglobin a1c in the diabetic mouse. Abstr. (1975) (1)
- Macrophage-Deactivating Agent Autoimmune Encephalomyelitis by CNI-1493 , a Prevention and Treatment of Experimental (1998) (1)
- Structure of lysine adducts with 16 alpha-hydroxyestrone and cortisol. (1986) (1)
- Studies on the mechanism of antimalarial action of a novel arylene bis(methylketone). (1997) (1)
- Advanced non-enzymatic tissue glycosylation: significance diabetic complications (1989) (1)
- [Risk factors of atherosclerosis in childhood]. (1985) (1)
- Advanced glycation end products contribute to amyloidosis in Alzheimer disease ( I-amyloid peptide / aggregation / nucleation-dependent kinetics / seed structure and function ) (1)
- a Nonerythropoietic Peptide Engineered from Erythropoietin , Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes (2015) (1)
- A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan (2023) (1)
- Assessment of diabetic control by measurement of urinary glycopeptides (1982) (1)
- 7 – Cachectin–TNF in the Biology of Disease (1991) (1)
- A novel Erythropoietin-derived peptide regulates Endothelial Progenitor Cell (EPC) mediated retinal vasorepair (2013) (1)
- A Surprising Journey in Translational Medicine (2014) (1)
- The Pathological Role of Cachectin/ Tumor Necrosis Factor in Septic Shock and Chronic Disease: In vivo Evidence (1988) (1)
- Advanced Non-Enzymatic Tissue Glycosylation: Biochemical Basis of Late Diabetic Complications (1989) (1)
- The primary site of apolipoprotein-B modification by advanced glycosylation endproducts (AGE-LDL) lies within a 28-kDa region located N-terminal to the LDL-receptor binding domain (1994) (0)
- NEUROTOKICITY OF SODIUM CYANATE: ULTRASTRUCTURAL ASPECTS (1978) (0)
- MIF IS AN IMPORTANT MEDIATOR OF THE TOXIC SHOCK SYNDROME.: 7 (1994) (0)
- Protective tissue peptides and uses thereof (2006) (0)
- [Not Available]. (1949) (0)
- Cerebral Effects of Erythropoietin (2003) (0)
- Reversal of the advanced glycosylierungsvernetzungen by use of heterocyclic substituted thiazolium (1999) (0)
- Host-parasite interface: biochemistry and rational drug design. (1990) (0)
- Identification of 2-Lactylamido-Guanine (LAG) as a DNA-Advanced Glycosylation Endproduct (2005) (0)
- Inhibitor of non-enzymatikc crosslinking (1988) (0)
- Delivery systems for dissolved substances with delayed release (2001) (0)
- Neuropathic pain and its treatment with ARA 290 and ketamine : overlapping pathways (2014) (0)
- endotoxin-induced decrease in lipoprotein lipase activity proceeds by a similar mech- anism. Exudate cells, in response to stimulation by endotoxin, release a mediator substance that causes a lowering of lipoprotein lipase activity in adipose tissue. Materials and Methods (2003) (0)
- Parasites, molecular biology, drug and vaccine design : proceedings of a UCLA Symposium held at Keystone, Colorado, April 3-10, 1989 (1990) (0)
- Editorial: "Propper" use of desferrioxamine. (1976) (0)
- Modulation of cellular stress response via the erythropoietin/CD131 heteroreceptor complex in mouse mesenchymal-derived cells (2014) (0)
- Pharmacology of cyanate. 3. Effects on the central nervous system. (1974) (0)
- Protective peptides and peptide analogs for tissue prevention and treatment of diseases and disorders associated with tissue damage (2009) (0)
- Cachectin/TNF: A Mediator of Lethal Endotoxemia (1987) (0)
- Sickle cell crisis during pregnancy in a patient with hemoglobin SD disease. (1981) (0)
- Abstract 9927: Helix B Surface Peptide, a Small Non-erythropoietic Molecule Based on the Erythropoietin Structure, Effectively Ameliorates the Progression of Chronic Heart Failure in the Rat Post Myocardial Infarction Model (2012) (0)
- A composition for promoting the kidnapping and removal of the body of an animal of macromolecules. (1987) (0)
- Rational development of new drugs for trypanosomiasis. (1979) (0)
- end products glycosylated and process related. (1988) (0)
- 1434 FEVER , TUMOR NECROSIS FACTOR (1986) (0)
- Management systems sustained release solutes. (2001) (0)
- A United States Patent 19 11 Patent Number : 6 , 110 , 968 (2017) (0)
- Glycosylated end products and related processes. (1988) (0)
- Safety And Efficacy Of Ara 290, A Non-erythropoietic Peptide Engineered From Erythropoietin, In Patients With Painful Diabetic Neuropathy. (2014) (0)
- Inhibition of the growth and differentiation of erythroid precursor cells by an endotoxin-induced mediator from peritoneal macrophages ( cell differentiation / growth inhibition / erythropoiesis / macrophage product ( s ) / murine erythroleukemia cells ) (0)
- Glucose as a Risk Factor for Atherosclerosis (1995) (0)
- P12 28 MP – EFFECT OF TRYPANOTHIONE ON THE BIOLOGICAL ACTIVITY OF IRRADIATED TRANSFORMING DNA (1991) (0)
- Method and means for inhibiting the Proteinveraltens. (1986) (0)
- Summary of patient data Age , Duration of years Race / sex diabetes , years Treatment Complications Type I diabetics 36 Black female 13 Insulin Diffuse severe atherosclerosis (0)
- Biochemical Studies of the Purine Analogues, 2-Aminopurine and 2, 6 Diaminopurine (2020) (0)
- Identification and characterization of macrophage inflammatory (2016) (0)
- Nonenzymatic glycosylation and browning of hemoglobin and other body proteins (1980) (0)
- Compounds and their use for the treatment of infectious diseases (1996) (0)
- POTENTIAL ANTITRYPANOSOMAL AGENTS. 1,N2-DISUBSTITUTED 2-AMINO-5-HYDROXY-4-METHYLNAPHTHO(1,2-D)THIAZOLIUM SALTS AND RELATED COMPOUNDS (1982) (0)
- [Retarded action dihydrostreptomycin associated with para-aminosalicylic acid in pulmonary tuberculosis]. (1950) (0)
- [A disease which is not always free of sequelae]. (1974) (0)
- Activity promoters colony stimulating factor. (1990) (0)
- Treatment of diabetic complications: Prevention of advanced nonenzymatic glycosylation of proteins (1989) (0)
- The ‘Senshu’ method often used to detect citrullinated proteins does not discriminate between citrullination and carbamylation (2012) (0)
- Reply to Abdelwahid and Smith: The effect on cardiomyocytes of helix B-surface peptide (HBSP), a peptide with cell-protective but not erythropoietic activities of erythropoietin (2011) (0)
- Detection of a novel cytokine in wound chambers by the polymerase chain reaction (1989) (0)
- Use of Thiazolium Compounds to Prevent and Reverse Formation of Long-End Glycosylation (1997) (0)
- Molecular basis for the cachexia of parasitic disease (1987) (0)
- Synthesis and NMR Characterization of the Trypanosomatid Metabolite, N1,N8-Bis(glutathionyl)spermidine Disulfide (Trypanothione Disulfide). (1990) (0)
- Protection, restoration and enhancement of cells, tissues and organs erythropoietin sensitive (2001) (0)
- Cell Surface Expression of Tumor Necrosis Factor/Cachectin by Activated Normal HumanT Cells (1990) (0)
- RAPID INDUCTION OF IL 1β mRNA IN EXPERIMENTAL COLITIS (1991) (0)
- For the article ‘ ‘ An advanced glycation end-product cross-link breaker can reverse age-related increases in myocardial stiffness (2000) (0)
- Stochastic seismic analysis of offshore towers (1984) (0)
- Chapter 9 ERYTHROPOIETIN IN SPINAL CORD INJURY Challenges for a novel neuroprotective strategy (0)
- Advanced glycosylation end products and corresponding methods. (1988) (0)
- A Forty-Year Odyssey in the Sea of Translational Medicine. (2014) (0)
- [Not Available]. (1949) (0)
- Preconditioning with a Non-erythropoietic Erythropoietin Ameliorates Spinal Cord Compressive Injury (2004) (0)
- Farewell Statement from Dr. Cerami and Dr. Tracey as Outgoing Co-Editors in Chief of Molecular Medicine (2014) (0)
- Similarity Drug Target Identification Using Side-Effect (2010) (0)
- Guanylhydrazone to treat inflammation (1995) (0)
- Guanylhydrazone for treatment of inflammation (1995) (0)
- [Silent asymptomatic spontaneous pneumothorax]. (1954) (0)
- to prevent use of thiazolium and reverse the formation of advanced glycosylation end products (1996) (0)
- The neuroprotective effect of erythropoietin (EPO) and of its non-erythropoietic carbamylated derivative (CEPO) in cisplatin-induced peripheral neurotoxicity (2006) (0)
- An inflammatory cytokine, method for measuring the binding sites, the test system, kit and use thereof. (1988) (0)
- imidazoliunsalze substituted and their use for the inhibition of protein aging (1997) (0)
- Protection and enhancement of cells, tissues and organs that respond to erythropoietin (2001) (0)
- 3T3-L1 adipocytes. mouse expression at the transcriptional level in downregulates lipoprotein lipase gene factor but not interleukin-1 alpha Recombinant human cachectin/tumor necrosis (2013) (0)
- ENDOTOXIN-INDUCED DECREASE IN LIPOPROTEIN LIPASE ACTIVITY Mice (0)
- Novel Applications for Recombinant Human Erythropoietin (2002) (0)
- Improvement of Metabolic Function after Intra-Portal Allogeneic Islet Transplantation Using Induction Treatment of the Non-Hematopoetic Erythropoietin Analogue Cibinetide in a Mouse Model (2018) (0)
- Vasoreparative potential of endothelial progenitor cells is enhanced by a novel erythropoietin (EPO) mimetic peptide. (2015) (0)
- Antibodies to a composition with mediator activity and its use in a pharmaceutical composition. (1982) (0)
- Differentially Regulated by Immunomodulatory Cytokines y-IFN, IL-10, IL-4, and TGF-,B (2007) (0)
- The McCarty Award in Molecular Medicine (1995) (0)
- Using thiazolium compounds to prevent and reverse the formation of advanced glycation end products. (1996) (0)
- Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis (2017) (0)
- Use of thiazoliumforbindelser to prevent change and the formation of advanced glycosylation (1996) (0)
- Erratum to: ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density (2016) (0)
- Modulator of the anabolic activity and its uses. (1986) (0)
- ROLE OF GLUCOSE IN DIABETIC COMPLICATIONS (1993) (0)
- Research on the action of some vegetable juices on the development of the Koch bacillus. (1949) (0)
- Macrophage-derived inflammatory mediators (MIP-1-alpha et MIP-1-beta) (1988) (0)
- Poster abstractIdentification of 4-hydroxyhexenal as an oxidation product formed during LDL advanced glycosylation (1994) (0)
- List of Contributors and Discussants (1981) (0)
- Guanylhydrazones for the treatment of inflammatory conditions. (1995) (0)
- Advanced Glycosylation of LDL: Role in Oxidative Modification and Diabetic Complications (2005) (0)
- Preconditioning with a Non-erythropoietic Erythropoietin Ameliorates Spinal Cord Compressive Injury (2004) (0)
- Clinical management of thalassemia. The status of new iron chelators. (1980) (0)
- 82. Suppressive effects of human proinflammatory cytokines on proliferation of human myeloid progenitor cells (1992) (0)
- TUMOR NECROSIS FACTOR IN LEISHMANIASIS a neutralizing anti-murine TNF antibody was (2003) (0)
- ARA 290 for Sarcoidosis and Painful Small Fiber Neuropathy (2016) (0)
- 5134 Antibody t Advanced Glycosylation End Products in Vivo experimentally induced diabetes and in the serum of diabetic individuals (2001) (0)
- [Not Available]. (1949) (0)
- Genetic influences on pancreas transplantation. (1983) (0)
- [Mass x-ray study of a group of ricecleaners of the Province of Modena]. (1955) (0)
- Additions and Corrections - Potential Anti-trypanosomal Agents. 1,N2-Disubstituted 2-Amino-5-hydroxy-4-methylnaphthol[1,2-d]thiazolium Salts and Related Compounds (1983) (0)
- Human immunodeficiency virus type 1 infection alters chemokine f 8 peptide expression in human monocytes : Implications for recruitment of leukocytes into brain and lymph nodes (0)
- Inhibition ofHemozoinFormationin Plasmodium falciparum Trophozoite Extracts byHeme Analogs: Possible Implication in theResistance toMalaria Conferred bythej3-Thalassemia Trait (1996) (0)
- Propper Use of Desferrioxamine (1976) (0)
- Compound for measuring protein ageing (1992) (0)
- Erythropoietin prevents neur cerebral ischemia and metab (2016) (0)
- Use Tiatsoliumyhdisteiden prevent and restore the formation of advanced glykosylointilopputuotteiden (1997) (0)
This paper list is powered by the following services:
Other Resources About Anthony Cerami
What Schools Are Affiliated With Anthony Cerami?
Anthony Cerami is affiliated with the following schools:
